Latest Derivatives News

State Street Global Advisors has announced a 21.5897 cents per unit cash distribution for the SPDR S&P/ASX Small Ordinaries ETF for the period ending June 30, 2025, alongside franking and foreign tax credits.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.

Westpac Banking Corporation has announced a fully franked distribution of AUD 1.2463 per Westpac Capital Note 9, reflecting a 4.9447% annualised rate for the quarter ending September 2025.

Westpac Banking Corporation announces a fully franked distribution of AUD 1.2463 per Capital Note 7 for Q3 2025, reflecting a 4.9447% annualised rate based on the 3-month BBSW plus margin.

Westpac Banking Corporation announces a fully franked distribution of AUD 1.2110 per Westpac Capital Notes 5 for the quarter ending September 2025, reflecting a 4.8047% annualised rate based on prevailing market benchmarks.

Munro Climate Change Leaders Fund Active ETF (ASX – MCCL) has released an estimated cash distribution of 302.3 cents per unit for the fiscal year ending 30 June 2025, signaling investor returns amid evolving market conditions.

Carnegie Clean Energy has secured $335,020 in funding from the Blue Economy CRC to progress the preliminary design of its MoorPower commercial pilot, aiming to revolutionize offshore aquaculture energy use.

PVW Resources has reported strong desorption test results from its Capão Bonito project in Brazil, confirming the presence of Ionic Adsorption Clay (IAC) style rare earth mineralisation with high recoveries of magnet rare earth oxides near surface.

Fletcher Building unveiled a comprehensive strategic review and FY25 outlook at its Investor Day, highlighting a focus on manufacturing and distribution alongside significant restructuring costs. The company targets a leaner operation with disciplined capital management and a net debt goal of NZD 400m to 900m.

INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.